Table 5. Predications of Mean Cost Attributable to Cancer^a.

	All ($)	Medicare Only ($)	Dually Eligible ($)	Difference ($) [95%CI]b
All patients	29196	29342	28070	1272c [−357, 2569]
Stage of Cancer
In situ/local	27551	27458	28063	−605 [−3866, 2126]
Regional	30748	30993	28943	2050c [−341, 4109]
Distant	29933	30326	26992	3335c [−64, 6438]
Procedure
None or Chemo	14696	14760	14276	483 [−2246, 3376]
Resection alone	28703	28822	27922	900 [−1074,2468]
Resection + Chemo	42523	42860	40322	2538 [−970, 6073]
Comorbidity
0	25205	25329	24220	1109c [−143,2167]
1	27967	28110	26830	1280c [−288, 2532]
2	28300	28465	26985	1480 [−573, 3044]
3+	32922	33125	31294	1832 [−1297,4273]
Stage of Cancer × Procedure
In situ/local × None or Chemo	10920	10844	11403	−560 [−3309, 1909]
In situ/local × Resection alone	27225	27105	27983	−878 [−4390, 1806]
In situ/local × Resection + Chemo	41426	41431	41403	28 [−5867, 4994]
Regional × None or Chemo	18101	18233	17238	995 [−2839, 4583]
Regional × Resection alone	30308	30543	28775	1768 [−1155, 4141]
Regional × Resection + Chemo	41624	42095	38540	3555d [182, 6677]
Distant × None or Chemo	15332	15546	13908	1638 [−1519, 4578]
Distant × Resection alone	27925	28300	25423	2877c [−644, 6166]
Distant × Resection + Chemo	45886	46634	40895	5740d [223, 11000]
Stage of Cancer × Comorbidity
In situ/local × 0	21583	21523	21960	−437 [−2734, 1542]
In situ/local × 1	23207	23141	23615	−474 [−2999, 1732]
In situ/local × 2	23272	23204	23685	−481 [−3002, 1730]
In situ/local × 3+	24239	24159	24683	−524 [−3295, 1779]
Regional × 0	27602	27789	26104	1685c [−296, 3439]
Regional × 1	25916	29971	27939	2032c [−303, 4165]
Regional × 2	28210	28467	26162	2305c [−409, 4813]
Regional × 3+	33611	33969	30756	3213c [−677, 6666]
Distant × 0	28090	28408	25557	2851d [12,5546]
Distant × 1	28522	28885	25635	3250c [−76, 6322]
Distant × 2	30367	30816	26787	4030c [−198, 7838]
Distant × 3+	25594	26103	21540	4563c [−452, 9088]

^aRecycled prediction approach was used except for the prediction for all patients (first row, first column).

^bBootstrap bias-corrected confidence intervals are used for testing equality in costs between Medicare only and dually eligible patients. 1,000 cluster bootstrapped samples were used where each cancer patient and the controls were considered one cluster in bootstrapping.

^cThe tests between Medicare only and the dually eligible patients were significant at p<0.1 using normal-based bootstrap confidence intervals.

^dThe tests between Medicare only and the dually eligible patients were significant at p<0.05 using normal-based bootstrap confidence intervals.

SOURCE: Michigan Tumor Resigtry, Medicare and Medicaid fee-for-service claims from 1996 to 2000.